arrow
P

Patricia Njuguna

GlaxoSmithKline
H指数:37
被引数:5,489

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Feasibility, safety, and impact of the RTS,S/AS01 E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi
LANCET
IF88.5
2024-04-015
OAAI
Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study
2022-09-0917
OAAI
Arterolane-piperaquine-mefloquine versus arterolane- piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial
2021-10-0111
OAAI
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination (vol 5, 32, 2020)
2020-10-060
OAAI
Observational study: 27years of severe malaria surveillance in Kilifi, Kenya
2019-07-0827
OAAI
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
2019-04-2343
OAAI
Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4
2018-03-0924
OAAI
A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country
2017-12-2289
OAAI
Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis
2017-03-0375
OAAI